A facile method for isolation of recombinant human apolipoprotein A-I from E. coli
[1];
- Children's Hospital Oakland Research Inst., Oakland CA (United States)
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States). Molecular Foundry
- California State Univ. (CalState), Long Beach, CA (United States). Dept. of Chemistry and Biochemistry
- McGill Univ. Health Centre, Montreal, QC (Canada). Research Inst.
Apolipoprotein (apo) A-I is the major protein component of high-density lipoprotein (HDL) and plays key roles in the Reverse Cholesterol Transport pathway. In the past decade, reconstituted HDL (rHDL) has been employed as a therapeutic agent for treatment of atherosclerosis. The ability of rHDL to promote cholesterol efflux from peripheral cells has been documented to reduce the size of atherosclerotic plaque lesions. However, development of apoA-I rHDL-based therapeutics for human use requires a cost effective process to generate an apoA-I product that meets “Good Manufacturing Practice” standards. Methods available for production and isolation of unmodified recombinant human apoA-I at scale are cumbersome, laborious and complex. To overcome this obstacle, a streamlined two-step procedure has been devised for isolation of recombinant untagged human apoA-I from E. coli that takes advantage of its ability to re-fold to a native conformation following denaturation. Heat treatment of a sonicated E. coli supernatant fraction induced precipitation of a large proportion of host cell proteins (HCP), yielding apoA-I as the major soluble protein. Reversed-phase HPLC of this material permitted recovery of apoA-I largely free of HCP and endotoxin. In conclusion, purified apoA-I possessed α-helix secondary structure, formed rHDL upon incubation with phospholipid and efficiently promoted cholesterol efflux from cholesterol loaded J774 macrophages.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC), Basic Energy Sciences (BES); National Institutes of Health (NIH)
- Grant/Contract Number:
- AC02-05CH11231; T32 DK061918; R37 HL-64159
- OSTI ID:
- 1379871
- Alternate ID(s):
- OSTI ID: 1416242
- Journal Information:
- Protein Expression and Purification, Vol. 134, Issue C; ISSN 1046-5928
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
High-efficient bacterial production of human ApoA-I amyloidogenic variants: Recombinant Human ApoA-I Amyloidogenic Variants
|
journal | November 2018 |
Single-Molecule 3D Images of “Hole-Hole” IgG1 Homodimers by Individual-Particle Electron Tomography
|
journal | June 2019 |
Similar Records
Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study
A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I